Sunshine Biopharma Inc (SBFM)
0.9355
+0.10
(+11.37%)
USD |
NASDAQ |
May 06, 12:00
Sunshine Biopharma Enterprise Value: -15.46M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | -15.46M |
| May 02, 2024 | -15.46M |
| May 01, 2024 | -15.44M |
| April 30, 2024 | -15.42M |
| April 29, 2024 | -15.44M |
| April 26, 2024 | -15.35M |
| April 25, 2024 | -15.49M |
| April 24, 2024 | -15.37M |
| April 23, 2024 | -15.09M |
| April 22, 2024 | -14.86M |
| April 19, 2024 | -14.54M |
| April 18, 2024 | -12.99M |
| April 17, 2024 | -12.51M |
| April 16, 2024 | -9.529M |
| April 15, 2024 | -10.22M |
| April 12, 2024 | -8.325M |
| April 11, 2024 | -7.629M |
| April 10, 2024 | -6.535M |
| April 09, 2024 | -6.794M |
| April 08, 2024 | -6.665M |
| April 05, 2024 | -6.147M |
| April 04, 2024 | -7.142M |
| April 03, 2024 | -5.501M |
| April 02, 2024 | -8.146M |
| April 01, 2024 | -5.700M |
| Date | Value |
|---|---|
| March 28, 2024 | -10.27M |
| March 27, 2024 | -10.62M |
| March 26, 2024 | -10.61M |
| March 25, 2024 | -10.56M |
| March 22, 2024 | -10.42M |
| March 21, 2024 | -10.32M |
| March 20, 2024 | -10.72M |
| March 19, 2024 | -10.82M |
| March 18, 2024 | -10.97M |
| March 15, 2024 | -10.32M |
| March 14, 2024 | -11.32M |
| March 13, 2024 | -11.25M |
| March 12, 2024 | -11.01M |
| March 11, 2024 | -10.57M |
| March 08, 2024 | -10.49M |
| March 07, 2024 | -10.25M |
| March 06, 2024 | -9.728M |
| March 05, 2024 | -7.977M |
| March 04, 2024 | -11.83M |
| March 01, 2024 | -13.27M |
| February 29, 2024 | -13.27M |
| February 28, 2024 | -13.23M |
| February 27, 2024 | -13.21M |
| February 26, 2024 | -13.19M |
| February 23, 2024 | -13.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-28.24M
Minimum
Oct 13 2022
117.21M
Maximum
May 25 2021
9.034M
Average
1.072M
Median
Oct 29 2019
Enterprise Value Benchmarks
| Lexaria Bioscience Corp | 35.17M |
| Acasti Pharma Inc | 2.708M |
| Aurinia Pharmaceuticals Inc | 378.91M |
| Edesa Biotech Inc | 10.43M |
| Xenon Pharmaceuticals Inc | 2.663B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.25M |
| Revenue (Quarterly) | 7.680M |
| Total Expenses (Quarterly) | 8.867M |
| EPS Diluted (Quarterly) | -5.70 |
| Gross Profit Margin (Quarterly) | 33.44% |
| Profit Margin (Quarterly) | -16.28% |
| Earnings Yield | -2.11K% |
| Normalized Earnings Yield | -2105.75 |